The antisense oligonucleotides market offers growth opportunities across diverse disease indications, with promising ...

Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseasesZURICH, SWITZERLAND, and ...

In this Teach Me in 10, Dr. Cody Palumbo, a Senior Application Scientist in Technical Design at TriLink BioTechnologies, discusses why gRNA purity matters and how advanced purification solutions can ...

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing: Santa Clara, California Wednesday, October 1, 2025, 09:00 Hrs [IST] Agilen ...

The phosphoramidites market shows promising growth in oligonucleotide synthesis, key to gene therapy and personalized ...

September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, ...

iconPCR is transforming PCR assay development. DOE research that at one point required dozens of plates and long hours at the ...

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide ...

By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William ...

THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France - September 29 ...